.png)
SummaryEURIPID is the closest thing Europe has to a single medicine price database, and you almost certainly cannot use it. It is a voluntary, explicitly non-profit cooperation of national pricing and reimbursement authorities, it holds official list prices at pack level from around 26 countries, and access is restricted to the authorities that submit their own national data. There is no research tier, no industry tier and no published fee schedule for external users. This article explains what EURIPID contains, who runs it, why the door is closed and what you can use instead.
EURIPID is co-led by two public institutions: the pharmacoeconomics department of Gesundheit Österreich GmbH in Vienna and the Hungarian health insurance fund NEAK. Funding comes from annual contributions paid by the participating authorities in equal shares, plus grants from the European Commission awarded in 2019 and in 2023. Governance runs through a Board of Participants, with one delegate per country plus the Commission, and an Executive Committee.
One detail matters if you plan to approach them. The same Vienna department that administers EURIPID also operates PPI, a commercial price information service. An enquiry about European price data therefore lands with an organisation that is both the custodian of the authority database and a vendor in the same market.
Sources: PPRI, Gesundheit Österreich and the European Commission STAMP presentation of 8 December 2017, both retrieved on 3 September 2026.
A WHO publication states 26 member countries for 2021. The named participant list from the 2017 Commission document covers Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, the Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland and the United Kingdom. Iceland supplied data without being a participant. Albania and Romania are listed as former participants.
The 2026 participant status is open. The operator website euripid.eu did not respond on 3 September 2026, across two tools and a direct request with a 25 second timeout, so the current list and the governance rules could not be inspected in full text. Every statement in this article therefore rests on operator secondary sources, a WHO publication and the Commission document.
The database holds official list prices of publicly reimbursed medicines, predominantly in the outpatient sector, published by the authorities in line with the EU Transparency Directive. The data model is explicitly pack based, which is the same architecture any serious cross-border price product needs.
| Element | Content |
|---|---|
| Identification | Product code, product name, package, company |
| Classification | ATC, pharmaceutical form, route of administration, INN, strengths, number of units |
| Price levels | Manufacturer price, wholesale price, net retail price, gross retail price |
| Derived fields | Price per unit for each level, plus conversion into another currency |
The important limitation sits in the price definition. These are list prices. Net prices in the sense of actually paid, discounted prices had not been implemented as of 2022, according to the WHO publication, although the European Parliament had called for them in 2017. Anyone comparing European prices at list level is therefore measuring the published price, not the paid price, and in markets with confidential rebates that gap can be substantial.
Access is limited to the national competent authorities of participating countries and to European Commission services, and only authorities that supply price data for their own country are eligible. No category for non governmental users, for research or for industry appears on any of the retrieved pages.
The Commission document states the reasons for the restriction explicitly:
The Board of Participants decides on access policy. For a commercial data product the consequence is structural rather than financial: eligibility requires being an authority and contributing national data. A fee would be payable if a fee existed, and none is published.
Three routes remain, and they differ in effort and in what they let you promise.
National sources directly. Every country publishes something, and the majority publish enough to work with. The trade-offs are price level, update frequency and licence status, which differ per country. Our country by country overview of what each European country publishes sets out all 30.
Commercial consolidations. Several vendors sell cross-country price data, including the Vienna PPI service already mentioned. The questions to ask are always the same: which price level, which coverage of the national universe, what update lag, and what redistribution rights.
A defined subset built in house. If the use case is narrow, for example ex-factory prices in six countries for a reference price basket, building from free national sources is realistic. Belgium, Finland, France, Italy, Norway and Sweden are the countries where the legal position is clear and the technical route is stable.
| EURIPID | National sources directly | |
|---|---|---|
| Who may use it | Authorities that submit their own data, plus Commission services | Anyone, subject to the licence terms of each country |
| Price levels | Four levels, harmonised, plus per unit and currency conversion | Whatever the country publishes, from ex-factory to retail including VAT |
| Coverage | Publicly reimbursed medicines, predominantly outpatient | Varies by country, often reimbursed only, France carries a price for 13,648 of 20,900 packs |
| Harmonisation | Done by the operator | Your own work, and the main cost driver |
| Currency handling | Converted field included | You convert, and you have to know that Denmark publishes in øre |
| Update rhythm | Depends on national submissions | Daily in Belgium, Portugal and Sweden, monthly in most countries, quarterly in Poland |
| Licence clarity | Not applicable, access is closed | Nine of 30 countries clear, four require a contract, ten undescribed |
The comparison explains why a closed authority database is not the loss it first appears to be. EURIPID removes harmonisation work, not data availability. The prices themselves are published nationally in nearly every participating country, because the EU Transparency Directive obliges member states to publish the decisions that set them.
If the authority route is closed and building from 30 national sources is too much, the remaining option is a commercial dataset. Four questions separate a usable product from a demo:
Two things. First, its data model is a sound blueprint: pack as the key, four price levels, per unit price and currency conversion as derived fields. Authorities and market access teams recognise this structure, which makes it a good internal standard.
Second, EURIPID publishes a guidance document on external reference pricing. That document is citable in methodology discussions even when the underlying database is closed, and external reference pricing is the mechanism that makes national prices depend on each other in the first place. We cover that mechanism in the article on how cross-border prices work.
EURIPID answers the question "do the authorities have a shared European price database" with yes, and the question "can I use it" with no. It holds pack level list prices from roughly 26 countries, it is run by two public institutions with Commission funding, and its access rules exist precisely to keep commercial users, parallel traders and price interpreters out. If you need European price data for professional use, the realistic path starts at the national sources, with the price level established first.
Related reading: European Drug Pricing Database: how cross-border prices work, drug prices by country and Pharma pricing Germany: how the system works.
pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. Price coverage focuses on the DACH region and a number of further EU countries, with more countries following in the coming months.
